Clinical Trial Detail

NCT ID NCT02656303
Title An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Recruitment Enrolling by invitation
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

chronic lymphocytic leukemia

Therapies

Ublituximab + Umbralisib

Age Groups: adult

No variant requirements are available.